Vol. 3 No. 11 (2023)
Reimbursement Reviews

Cenobamate (Xcopri)

Published November 29, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cenobamate (Xcopri), 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg tablet, oral.
  • Indication: As adjunctive therapy in the management of partial onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.